

Revision date: 05-Jan-2007 Version: 1.2 Page 1 of 5

## IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc
Pfizer Inc
Pfizer Pharmaceuticals Group
Ramsgate Road
235 East 42nd Street
Sandwich, Kent
New York, New York 10017
CT13 9NJ
1-212-573-2222
United Kingdom
+00 44 (0)1304 616161

Emergency telephone number: Emergency telephone number:

Material Name: Calcium Folinate (Leucovorin Calcium) Tablets

Trade Name: Refolinon Chemical Family: Mixture

Intended Use: Antidote to folic acid antagonists

## 2. COMPOSITION/INFORMATION ON INGREDIENTS

#### **Hazardous**

Ingredient	CAS Number	<b>EU EINECS List</b>	%
Magnesium stearate	557-04-0	209-150-3	*
Microcrystalline cellulose	9004-34-6	232-674-9	*

Ingredient	CAS Number	<b>EU EINECS List</b>	%
Calcium Folinate	1492-18-8	216-082-8	15 mg***
Lactose	63-42-3	200-559-2	*

Additional Information: \* Proprietary

\*\*\* per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

## 3. HAZARDS IDENTIFICATION

Appearance: White tablets Signal Word: WARNING

Statement of Hazard: May cause respiratory tract irritation

**Additional Hazard Information:** 

**Known Clinical Effects:** 

**Short Term:** Not acutely toxic (based on components).

**Long Term:** Prolonged or repeated inhalation may cause nose, throat and lung irritation.

Ingestion of this material may cause effects similar to those seen in clinical use including effects on gastrointestinal disturbances and abdominal pain. Hypersensitivity reactions may

also occur in susceptible individuals.

EU Indication of danger: Not classified

Material Name: Calcium Folinate (Leucovorin Calcium) Page 2 of 5

**Tablets** 

Revision date: 05-Jan-2007 Version: 1.2

**Note:** This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

## 4. FIRST AID MEASURES

Eye Contact: Flush eyes with water for at least 15 minutes. If irritation occurs or persists, get medical

attention.

**Skin Contact:** Wash skin with soap and water. If irritation occurs or persists, get medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

**Inhalation:** Remove to fresh air and keep patient at rest. Seek medical attention immediately.

## 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: May emit toxic fumes of oxides of carbon and nitrogen.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Not applicable

## 6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

**Measures for Cleaning / Collecting:** Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Measures for Environmental** 

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

**Additional Consideration for Large** 

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

**General Handling:** If tablets or capsules are crushed and/or broken, avoid breathing dust and avoid contact with

eyes.

**Storage Conditions:** Store as directed by product packaging.

### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Magnesium stearate

ACGIH Threshold Limit Value (TWA)

= 10 mg/m<sup>3</sup> TWA except stearates of toxic metals

Material Name: Calcium Folinate (Leucovorin Calcium) Page 3 of 5

**Tablets** 

Revision date: 05-Jan-2007 Version: 1.2

Australia TWA = 10 mg/m<sup>3</sup> TWA

Microcrystalline cellulose

OSHA - Final PELS - TWAs: = 15 mg/m³ TWA total

= 5 mg/m<sup>3</sup> TWA

ACGIH Threshold Limit Value (TWA) = 10 mg/m³ TWA Australia TWA = 10 mg/m³ TWA

The exposure limit(s) listed for solid components are only relevant if dust may be generated.

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures.

**Personal Protective Equipment:** 

**Hands:** Not required for the normal use of this product. Wear protective gloves when working with

large quantities.

**Eyes:** Not required for the normal use of this product. Wear safety glasses or goggles if eye contact

is possible.

Skin: Not required for the normal use of this product. Wear protective clothing when working with

large quantities.

**Respiratory protection:** None required under normal conditions of use. Not required for the normal use of this product.

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

## 9. PHYSICAL AND CHEMICAL PROPERTIES:

Physical State:TabletsColor:WhiteMolecular Formula:MixtureMolecular Weight:Mixture

## 10. STABILITY AND REACTIVITY

**Stability:** Stable under normal conditions of use.

Conditions to Avoid: Not determined

**Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers.

### 11. TOXICOLOGICAL INFORMATION

**General Information:** The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

**Calcium Folinate** 

Rat Oral LD 50 > 8000 mg/kg Mouse Oral LD 50 > 7000 mg/kg Rat Intraperitoneal LD 50 1063 mg/kg

Lactose

Rat Oral LD50 > 10 g/kg

Microcrystalline cellulose

Material Name: Calcium Folinate (Leucovorin Calcium) Page 4 of 5

**Tablets** 

Revision date: 05-Jan-2007 Version: 1.2

Rat Oral LD50 > 5000 mg/kg Rabbit Dermal LD50 > 2000 mg/kg

Magnesium stearate

Rat Oral LD50 > 2000 mg/kg Rat Inhalation LC50 > 2000 mg/m<sup>3</sup>

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

<u>Irritation / Sensitization: (Study Type, Species, Severity)</u>

Microcrystalline cellulose

Skin Irritation Rabbit Non-irritating Eye Irritation Rabbit Non-irritating

Carcinogen Status: None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

## 12. ECOLOGICAL INFORMATION

**Environmental Overview:** Environmental properties have not been investigated. Releases to the environment should be

avoided.

## 13. DISPOSAL CONSIDERATIONS

**Disposal Procedures:** Dispose of waste in accordance with all applicable laws and regulations.

## 14. TRANSPORT INFORMATION

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## 15. REGULATORY INFORMATION

EU Indication of danger: Not classified

**OSHA Label:** 

WARNING

May cause respiratory tract irritation

Canada - WHMIS: Classifications

Material Name: Calcium Folinate (Leucovorin Calcium) Page 5 of 5

**Tablets** 

Revision date: 05-Jan-2007 Version: 1.2

#### WHMIS hazard class:

Class D, Division 2, Subdivision B



**Calcium Folinate** 

Australia (AICS): Present EU EINECS List 216-082-8

Lactose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

Present
200-559-2

Magnesium stearate

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS List

209-150-3

Microcrystalline cellulose

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

EU EINECS List

XU

Present
232-674-9

## 16. OTHER INFORMATION

**Reasons for Revision:** Updated Section 3 - Hazard Identification. Updated Section 5 - Fire Fighting Measures.

Updated Section 8 - Exposure Controls / Personal Protection. Updated Section 10 - Stability and Reactivity. Updated Section 11 - Toxicology Information. Updated Section 13 - Disposal

Considerations.

Prepared by: Toxicology and Hazard Communication

Pfizer Global Environment, Health, and Safety

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied.

**End of Safety Data Sheet**